Patents Assigned to BIO-THERA SOLUTIONS, LTD., CO.
-
Publication number: 20170258935Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.Type: ApplicationFiled: May 26, 2017Publication date: September 14, 2017Applicant: Bio-Thera Solutions, Ltd., Co.Inventors: Weijia Tang, Shengfeng Li, Jin-Chen Yu, Xiaobin Deng
-
Patent number: 9737616Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.Type: GrantFiled: July 17, 2015Date of Patent: August 22, 2017Assignee: Bio-Thera Solutions, Ltd., Co.Inventors: Weijia Tang, Shengfeng Li, Jin-Chen Yu, Xiaobin Deng
-
Patent number: 9345786Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.Type: GrantFiled: March 15, 2013Date of Patent: May 24, 2016Assignee: Bio-Thera Solutions, Ltd., Co.Inventors: Shengfeng Li, Xiaobin Deng, Songnuan Tan, Weijia Tang, Chao Qin
-
Patent number: 9314536Abstract: Disclosed herein are anti-EGFR antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat EGFR positive cells in cancers are provided.Type: GrantFiled: March 15, 2013Date of Patent: April 19, 2016Assignee: Bio-Thera Solutions, Ltd., Co.Inventors: Chao Qin, Shengfeng Li
-
Publication number: 20150320881Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.Type: ApplicationFiled: July 17, 2015Publication date: November 12, 2015Applicant: BIO-THERA SOLUTIONS, LTD., CO.Inventors: Weijia Tang, Shengfeng Li, Jin-Chen Yu, Xiaobin Deng
-
Patent number: 8889855Abstract: Provided are efficient methods for direct coupling of a maytansinoid with a carboxylic acid to prepare a maytansinoid C-3 ester in high yield using a rare earth metal-based or trifluoromethanesulfonate-based Lewis acid catalyst and a base together with a coupling reagent. Also provided are compositions used in such methods.Type: GrantFiled: March 15, 2013Date of Patent: November 18, 2014Assignee: Bio-Thera Solutions Ltd., Co.Inventor: Xiaobin Deng
-
Patent number: 8877706Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.Type: GrantFiled: March 15, 2013Date of Patent: November 4, 2014Assignee: Bio-Thera Solutions Ltd., Co.Inventors: Shenfeng Li, Xiaobin Deng, Songnuan Tan, Weijia Tang, Chao Qin
-
Publication number: 20140179917Abstract: Provided are efficient methods for direct coupling of a maytansinoid with a carboxylic acid to prepare a maytansinoid C-3 ester in high yield using a rare earth metal-based or trifluoromethanesulfonate-based Lewis acid catalyst and a base together with a coupling reagent. Also provided are compositions used in such methods.Type: ApplicationFiled: March 15, 2013Publication date: June 26, 2014Applicant: BIO-THERA SOLUTIONS, LTD., CO.Inventor: Xiaobin DENG
-
Publication number: 20140178413Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.Type: ApplicationFiled: March 15, 2013Publication date: June 26, 2014Applicant: BIO-THERA SOLUTIONS, LTD., CO.Inventor: Bio-Thera Solutions, Ltd. Co.
-
Publication number: 20140178414Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.Type: ApplicationFiled: March 15, 2013Publication date: June 26, 2014Applicant: BIO-THERA SOLUTIONS, LTD., CO.Inventor: BIO-THERA SOLUTIONS, LTD., CO.
-
Publication number: 20140178411Abstract: Disclosed herein are anti-CD20 antibody conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat CD20 positive cells in cancers are provided.Type: ApplicationFiled: March 15, 2013Publication date: June 26, 2014Applicant: BIO-THERA SOLUTIONS, LTD., CO.Inventors: Chao Qin, Shengfeng Li